Abrdn Life Sciences Investors (N:HQL)

Sector:  Financials Industry:  Closed End Funds
 
See Regulatory Filings on SEC
Company Contact
Address: 1900 Market Street, Suite 200
PHILADELPHIA PA 19103
Tel: N/A
Website: https://www.teklacap.com/funds/hql/fund/fund-information
IR: See website
<
Key People
Daniel R. Omstead
President, Trustee 		Laura Woodward
Chief Compliance Officer, Treasurer, Secretary 		 
Business Overview
abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.
Financial Overview
For the fiscal year ended 30 September 2023, Abrdn Life Sciences Investors revenues increased 16% to $3.5M. Net income totaled $22.4M vs. loss of $104.6M. Revenues reflect Interest and other income increase from $50K to $204K, Dividend income increase of 1% to $2.9M. Net Income reflects Investments in affiliated issuers decrease of 88% to $15.3M (expense), Net realized gain increase of 43% to $35.9M (income).
Reporting Currency: U.S. Dollars
Enterprise value: $336.04M as of Sep 30, 2023
Annual revenue (TTM): $3.50M as of Sep 30, 2023
EBITDA (TTM): -$2.18M as of Sep 30, 2023
Net annual income (TTM): $22.35M as of Sep 30, 2023
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 26,791,197 as of Sep 30, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More